Anaphylaxis: Lessons from mouse models

Journal of Allergy and Clinical Immunology

Volumn 120, Issue 3, 2007, Pages 506-515

  Finkelman, Fred D ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Allergy; anaphylaxis; Fc RIIb; Fc RIII; IgE; IgG; IL 13; IL 4; mouse; nitric oxide

Indexed keywords

ANTIBODY; ANTIGEN; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FC RECEPTOR; FOOD ALLERGEN; HISTAMINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4 RECEPTOR ALPHA; ION CHANNEL; NITRIC OXIDE; OMALIZUMAB; SEROTONIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TYROSINE DERIVATIVE;

ANAPHYLAXIS; ANTIGEN BINDING; CROSS LINKING; DIARRHEA; HUMAN; INNATE IMMUNITY; INTESTINAL ANAPHYLAXIS; MACROPHAGE; MAST CELL; MODEL; NONHUMAN; PEANUT; PENICILLIN INDUCED ANAPHYLAXIS; PRIORITY JOURNAL; REVIEW; SKIN ANAPHYLAXIS;

ANAPHYLAXIS; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MICE; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY;

EID: 34548361747     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2007.07.033     Document Type: Review

References (85)

1. Simons F.E.R., Frew A.J., Ansotegui I.J., Bochner B.S., Golden D.B.K., Finkelman F.D., et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 120 suppl (2007) S1-S24
2. Weiler J.M. Anaphylaxis in the general population: a frequent and occasionally fatal disorder that is underrecognized. J Allergy Clin Immunol 104 (1999) 271-273
3. Strait R.T., Morris S.C., Yang M., Qu X.W., and Finkelman F.D. Pathways of anaphylaxis in the mouse. J Allergy Clin Immunol 109 (2002) 658-668
4. Strait R.T., Morris S.C., and Finkelman F.D. IgG Blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and FcγRIIb crosslinking. J Clin Invest 116 (2006) 833-841
5. Ishizaka T., and Conrad D.H. Binding characteristics of human IgE receptors and initial triggering events in human mast cells for histamine release. Monogr Allergy 18 (1983) 14-24
6. Wastling J.M., Knight P., Ure J., Wright S., Thornton E.M., Scudamore C.L., et al. Histochemical and ultrastructural modification of mucosal mast cell granules in parasitized mice lacking the beta-chymase, mouse mast cell protease-1. Am J Pathol 153 (1998) 491-504
7. Lazar Jr. G., Lazar G., Kaszaki J., Olah J., Kiss I., and Husztik E. Inhibition of anaphylactic shock by gadolinium chloride-induced Kupffer cell blockade. Agents Actions 41 (1994) C97-C98
8. Jenei B., Lazar G., Bartha K., and Medgyesi G.A. Hypotensive action of IgG preparations containing aggregates is suppressed by PAF-receptor antagonist BN 52021 and by gadolinium chloride (an agent blocking Kupffer cell function). Agents Actions 32 (1991) 333-338
9. Hazenbos W.L., Gessner J.E., Hofhuis F.M., Kuipers H., Meyer D., Heijnen I.A., et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in FcγRIII (CD16) deficient mice. Immunity 5 (1996) 181-188
10. Hazenbos W.L., Heijnen I.A., Meyer D., Hofhuis F.M., Renardel de Lavalette C.R., Schmidt R.E., et al. Murine IgG1 complexes trigger immune effector functions predominantly via FcγRIII (CD16). J Immunol 161 (1998) 3026-3032
11. Terashita Z.-I., Imura Y., Shino A., and Nishikawa K. A lethal role of platelet activating factor in anaphylactic shock in mice. J Pharmacol Exp Ther 234 (1987) 378-383
12. Oettgen H.C., Martin T.R., Wynshaw-Boris A., Deng C., Drazen J.M., and Leder P. Active anaphylaxis in IgE-deficient mice. Nature 370 (1994) 367-370
13. Takai T., Ono M., Hikida M., Ohmori H., and Ravetch J.V. Augmented humoral and anaphylactic responses in FcγRII-deficient mice. Nature 379 (1996) 346-349
14. Miyajima I., Dombrowicz D., Martin T.R., Ravetch J.V., Kinet J.P., and Galli S.J. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and FcγRIII. Assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE- or IgG1- dependent passive anaphylaxis. J Clin Invest 99 (1997) 901-914
15. Ravetch J.V., and Bolland S. IgG Fc receptors. Annu Rev Immunol 19 (2001) 275-290
16. Ha T.Y., Reed N.D., and Crowle P.K. Immune response potential of mast cell-deficient W/Wv mice. Int Arch Allergy Appl Immunol 80 (1986) 85-90
17. Dombrowicz D., Flamand V., Miyajima I., Ravetch J.V., Galli S.J., and Kinet J.P. Absence of FcεRI α chain results in upregulation of FcγRIII-dependent mast cell degranulation and anaphylaxis. Evidence of competition between FcεRI and FcγRIII for limiting amounts of FcR β and γ chains. J Clin Invest 99 (1997) 915-925
18. Takai T., Li M., Sylvestre D., Clynes R., and Ravetch J.V. FcR γ chain deletion results in pleiotrophic effector cell defects. Cell 76 (1994) 519-529
19. Martin T.R., Ando A., Takeishi T., Katona I., Drazen J., and Galli S. Mast cells contribute to the changes in heart rate, but not hypotension or death, associated with active anaphylaxis in mice. J Immunol 151 (1993) 367-376
20. Feuerstein G., and Siren A.L. Platelet-activating factor and shock. Prog Biochem Pharmacol 22 (1988) 181-190
21. Fish S.C., Donaldson D.D., Goldman S.J., Williams C.M., and Kasaian M.T. IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13. J Immunol 174 (2005) 7716-7724
22. Kinet J.P. The high-affinity IgE receptor (FcεRI): from physiology to pathology. Annu Rev Immunol 17 (1999) 931-972
23. Nimmerjahn F., and Ravetch J.V. Divergent Immunoglobulin G subclass activity through selective Fc receptor binding. Science 310 (2005) 1510-1512
24. Choi I.H., Shin Y.M., Park J.S., Lee M.S., Han E.H., Chai O.H., et al. Immunoglobulin E-dependent active fatal anaphylaxis in mast cell-deficient mice. J Exp Med 188 (1998) 1587-1592
25. Liu E., Moriyama H., Abiru N., Miao D., Yu L., Taylor R.M., et al. Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J Clin Invest 110 (2002) 1021-1027
26. Ujike A., Ishikawa Y., Ono M., Yuasa T., Yoshino T., Fukumoto M., et al. Modulation of immunoglobulin (Ig)E-mediated systemic anaphylaxis by low-affinity Fc receptors for IgG. J Exp Med 189 (1999) 1573-1579
27. Bachelet I., Munitz A., Moretta A., Moretta L., and Levi-Schaffer F. The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. J Immunol 175 (2005) 7989-7995
28. Maeda A., Kurosaki M., and Kurosaki T. Paired immunoglobulin-like receptor (PIR)-A is involved in activating mast cells through its association with Fc receptor γ chain. J Exp Med 188 (1998) 991-995
29. Udell C.M., Samayawardhena L.A., Kawakami Y., Kawakami T., and Craig A.W. Fer and Fps/Fes participate in a Lyn-dependent pathway from FcεRI to platelet-endothelial cell adhesion molecule 1 to limit mast cell activation. J Biol Chem 281 (2006) 20949-20957
30. Licht A., Pecht I., and Schweitzer-Stenner R. Regulation of mast cells' secretory response by co-clustering the Type 1 Fcε receptor with the mast cell function-associated antigen. Eur J Immunol 35 (2005) 1621-1633
31. Feldweg A.M., Friend D.S., Zhou J.S., Kanaoka Y., Daheshia M., Li L., et al. gp49B1 suppresses stem cell factor-induced mast cell activation-secretion and attendant inflammation in vivo. Eur J Immunol 33 (2003) 2262-2268
32. Takai T. Paired immunoglobulin-like receptors and their MHC class I recognition. Immunology 115 (2005) 433-440
33. Zhang S., Cherwinski H., Sedgwick J.D., and Phillips J.H. Molecular mechanisms of CD200 inhibition of mast cell activation. J Immunol 173 (2004) 6786-6793
34. Hua X., Kovarova M., Chason K.D., Nguyen M., Koller B.H., and Tilley S.L. Enhanced mast cell activation in mice deficient in the A2b adenosine receptor. J Exp Med 204 (2007) 117-128
35. Vennekens R., Olausson J., Meissner M., Bloch W., Mathar I., Philipp S.E., et al. Increased IgE-dependent mast cell activation and anaphylactic responses in mice lacking the calcium-activated nonselective cation channel TRPM4. Nat Immunol 8 (2007) 312-320
36. Franke T.F., Yang S.I., Chan T.O., Datta K., Kazlauskas A., Morrison D.K., et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81 (1995) 727-736
37. Cauwels A., Janssen B., Buys E., Sips P., and Brouckaert P. Anaphylactic shock depends on PI3K and eNOS-derived NO. J Clin Invest 116 (2006) 2244-2251
38. Khodoun M.V., Orekhova T., Potter C., Morris S., and Finkelman F.D. Basophils initiate IL-4 production during a memory T-dependent response. J Exp Med 200 (2004) 857-870
39. Nelms K., Keegan A.D., Zamorano J., Ryan J.J., and Paul W.E. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 17 (1999) 701-738
40. Kaplan M.H., Schindler U., Smiley S.T., and Grusby M.J. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4 (1996) 313-319
41. Strait R.T., Morris S.C., Smiley K., Urban Jr. J.F., and Finkelman F.D. IL-4 exacerbates anaphylaxis. J Immunol 170 (2003) 3835-3842
42. Breslow M.J., and Ligier B. Hyperadrenergic states. Crit Care Med 19 (1991) 1566-1579
43. Sampson H.A. Anaphylaxis and emergency treatment. Pediatrics 111 (2003) 1601-1608
44. Lang D.M. Anaphylactoid and anaphylactic reactions. Hazards of β-blockers. Drug Saf 12 (1995) 299-304
45. Cockcroft J.R., Gazis A.G., Cross D.J., Wheatley A., Dewar J., Hall I.P., et al. β2-adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension 36 (2000) 371-375
46. Schafer T., Bohler E., Ruhdorfer S., Weigl L., Wessner D., Heinrich J., et al. Epidemiology of food allergy/food intolerance in adults: associations with other manifestations of atopy. Allergy 56 (2001) 1172-1179
47. Wood R.A. The natural history of food allergy. Pediatrics 111 (2003) 1631-1637
48. Li X.M., Serebrisky D., Lee S.Y., Huang C.K., Bardina L., Schofield B.H., et al. A murine model of peanut anaphylaxis: T- and B-cell responses to a major peanut allergen mimic human responses. J Allergy Clin Immunol 106 (2000) 150-158
49. Brandt E.B., Strait R.T., Hershko D., Wang Q., Muntel E.E., Scribner T.A., et al. Mast cells are required for experimental oral allergen-induced diarrhea. J Clin Invest 112 (2003) 1666-1677
50. Birmingham N.P., Parvataneni S., Hassan H.M., Harkema J., Samineni S., Navuluri L., et al. An adjuvant-free mouse model of tree nut allergy using hazelnut as a model tree nut. Int Arch Allergy Immunol 144 (2007) 203-210
51. Sen M., Kopper R., Pons L., Abraham E.C., Burks A.W., and Bannon G.A. Protein structure plays a critical role in peanut allergen stability and may determine immunodominant IgE-binding epitopes. J Immunol 169 (2002) 882-887
52. Maleki S.J., Kopper R.A., Shin D.S., Park C.W., Compadre C.M., Sampson H., et al. Structure of the major peanut allergen Ara h 1 may protect IgE-binding epitopes from degradation. J Immunol 164 (2000) 5844-5849
53. Sampson H.A., Mendelson L., and Rosen J.P. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 327 (1992) 380-384
54. Sampson H.A. Food anaphylaxis. Br Med Bull 56 (2000) 925-935
55. Shreffler W.G., Castro R.R., Kucuk Z.Y., Charlop-Powers Z., Grishina G., Yoo S., et al. The major glycoprotein allergen from Arachis hypogaea, Ara h 1, is a ligand of dendritic cell-specific ICAM-grabbing nonintegrin and acts as a Th2 adjuvant in vitro. J Immunol 177 (2006) 3677-3685
56. van Wijk F., Nierkens S., Hassing I., Feijen M., Koppelman S.J., de Jong G.A., et al. The effect of the food matrix on in vivo immune responses to purified peanut allergens. Toxicol Sci 86 (2005) 333-341
57. Ovary Z. Immediate hypersensitivity. A brief, personal history. Arerugi 43 (1994) 1375-1385
58. Ishizaka K., and Ishizaka T. Biological function of gamma E antibodies and mechanisms of reaginic hypersensitivity. Clin Exp Immunol 6 (1970) 25-42
59. Faquim-Mauro E.L., Coffman R.L., Abrahamsohn I.A., and Macedo M.S. Cutting edge: mouse IgG1 antibodies comprise two functionally distinct types that are differentially regulated by IL-4 and IL-12. J Immunol 163 (1999) 3572-3576
60. Park J.S., Choi I.H., Lee D.G., Han S.S., Ha T.Y., Lee J.H., et al. Anti-IL-4 monoclonal antibody prevents antibiotics-induced active fatal anaphylaxis. J Immunol 158 (1997) 5002-5006
61. Finkelman F.D., Rothenberg M.E., Brandt E.B., Morris S.C., and Strait R.T. Molecular mechanisms of anaphylaxis: lessons from studies with murine models. J Allergy Clin Immunol 115 (2005) 449-457
62. Maurer D., Fiebiger E., Reininger B., Wolff-Winiski B., Jouvin M.H., Kilgus O., et al. Expression of functional high affinity immunoglobulin E receptors (FcεRI) on monocytes of atopic individuals. J Exp Med 179 (1994) 745-750
63. Snapper C., and Finkelman F. Immunoglobulin class switching. In: Paul W.E. (Ed). Fundamental immunology (1999), Lippincott-Raven, Philadelphia
64. Dahinden C.A., Kurimoto Y., and Wirthmuller U. Growth factors, lipid mediators and effector cells. J Lipid Mediat 2 suppl (1990) S129-S136
65. + T helper cell phenotype development in a T cell receptor-αβ-transgenic model. J Exp Med 182 (1995) 1579-1584
66. Ring J., and Darsow U. Idiopathic anaphylaxis. Curr Allergy Asthma Rep 2 (2002) 40-45
67. Dybendal T., Guttormsen A.B., Elsayed S., Askeland B., Harboe T., and Florvaag E. Screening for mast cell tryptase and serum IgE antibodies in 18 patients with anaphylactic shock during general anaesthesia. Acta Anaesthesiol Scand 47 (2003) 1211-1218
68. Golden D.B. Patterns of anaphylaxis: acute and late phase features of allergic reactions. Novartis Found Symp 257 (2004) 101-110 discussion 10-5, 57-60, 276-85
69. Cheifetz A., Smedley M., Martin S., Reiter M., Leone G., Mayer L., et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 98 (2003) 1315-1324
70. Stallmach A., Giese T., Schmidt C., Meuer S.C., and Zeuzem S.S. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab-report of a case. Eur J Gastroenterol Hepatol 16 (2004) 627-630
71. Dreyfus D.H., and Randolph C.C. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol 96 (2006) 624-627
72. Leung D.Y., Sampson H.A., Yunginger J.W., Burks Jr. A.W., Schneider L.C., Wortel C.H., et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348 (2003) 986-993
73. Duplay D. Physician's desk reference. 58th ed. (2004), Thomson PDT, Montvale (NJ)
74. Gomez F.P., Marrades R.M., Iglesia R., Roca J., Barbera J.A., Chung K.F., et al. Gas exchange response to a PAF receptor antagonist, SR 27417A, in acute asthma: a pilot study. Eur Respir J 14 (1999) 622-626
75. Danko G., Sherwood J.E., Grissom B., Kreutner W., and Chapman R.W. Effect of the PAF antagonists, CV-3988 and L-652,731 on the pulmonary and hematological responses to guinea pig anaphylaxis. Pharmacol Res Commun 20 (1988) 785-798
76. Duschl A., Muller T., and Sebald W. Antagonistic mutant proteins of interleukin-4. Behring Inst Mitt (1995) 87-94
77. Beckmann M.P., Schooley K.A., Gallis B., Vanden Bos T., Friend D., Alpert A.R., et al. Monoclonal antibodies block murine IL-4 receptor function. J Immunol 144 (1990) 4212-4217
78. Lee S.Y., Huang C.K., Zhang T.F., Schofield B.H., Burks A.W., Bannon G.A., et al. Oral administration of IL-12 suppresses anaphylactic reactions in a murine model of peanut hypersensitivity. Clin Immunol 101 (2001) 220-228
79. Frossard C.P., Steidler L., and Eigenmann P.A. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J Allergy Clin Immunol 119 (2007) 952-959
80. Zhu D., Kepley C.L., Zhang M., Zhang K., and Saxon A. A novel human immunoglobulin Fcγ Fcε bifunctional fusion protein inhibits FcεRI-mediated degranulation. Nat Med 8 (2002) 518-521
81. Zhang K., Kepley C.L., Terada T., Zhu D., Perez H., and Saxon A. Inhibition of allergen-specific IgE reactivity by a human Ig Fcγ-Fcε bifunctional fusion protein. J Allergy Clin Immunol 114 (2004) 321-327
82. Bachelet I., Munitz A., and Levi-Schaffer F. Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. J Allergy Clin Immunol 117 (2006) 1314-1320
83. Ong C.J., Ming-Lum A., Nodwell M., Ghanipour A., Yang L., Williams D.E., et al. Small molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood (2007) May 14 [epub ahead of print]
84. Buchanan A.D., Green T.D., Jones S.M., Scurlock A.M., Christie L., Althage K.A., et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J Allergy Clin Immunol 119 (2007) 199-205
85. Nash S.D., Steele P.H., Kamilaris J.S., Pons L., Kulis M., Lee L.A., et al. Oral peanut immunotherapy for peanut allergic patients. J Allergy Clin Immunol 119 suppl (2007) S158